Grantsville (UT)
{name}
{subtitle}
A Clinical Trial of Three Study Medicines (Encorafenib, Binimetinib, and Pembrolizumab) in Patients With Advanced or Metastatic Melanoma
city
~34 mi. (West Valley City, Utah, +59 more cities)
facility
Utah Cancer Specialists
biomarker
BRAF V600E, +1 more biomarker
condition
Cutaneous Melanoma
drug
binimetinib, +2 more drugs
drug type
immunotherapy, +1 more type
Study of Olaparib (MK-7339) in Combination With Pembrolizumab (MK-3475) in the Treatment of Homologous Recombination Repair Mutation (HRRm) and/or Homologous Recombination Deficiency (HRD)-Positive Advanced Cancer (MK-7339-007/KEYLYNK-007)
city
~34 mi. (West Valley City, Utah, +115 more cities)
facility
Utah Cancer Specialists ( Site 0038)
biomarker
ATM Loss, +27 more biomarkers
condition
Breast Carcinoma, +2 more conditions
drug
olaparib, +1 more drug
drug type
immunotherapy, +1 more type
A Study Evaluating the Safety, Pharmacokinetics, and Preliminary Efficacy of Orally Administered SM08502 Combined With Hormonal Therapy or Chemotherapy in Subjects With Advanced Solid Tumors
city
~34 mi. (West Valley City, Utah, +19 more cities)
facility
START Mountain Region
condition
Colorectal Carcinoma, +2 more conditions
drug
abiraterone, +5 more drugs
drug type
chemotherapy, +2 more types
Study of JTX 8064, as Monotherapy and in Combination With a PD-1 Inhibitor, in Adult Subjects With Advanced Refractory Solid Tumors
city
~34 mi. (West Valley City, Utah, +32 more cities)
facility
START Mountain Region
biomarker
ALK Fusion, +11 more biomarkers
condition
Breast Carcinoma, +3 more conditions
drug
JTX-8064, +1 more drug
drug type
immunotherapy
A Phase 1/2 Study Evaluating MCLA-129, a Human Anti-EGFR and Anti-c-MET Bispecific Antibody, in Patients With Advanced NSCLC and Other Solid Tumors
city
~34 mi. (West Valley City, Utah, +1 more cities)
facility
START Mountain Region
condition
Malignant Solid Tumor
drug
MCLA-129
drug type
targeted therapy